Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2009 1
2012 1
2014 1
2015 1
2019 1
2021 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
de Vos II, Marenghi C, Badenchini F, Boevé ER, Lozano-Uruñuela F, Graefen M, Rannikko AS, Staerman F, Sugimoto M, Kato T, Somford DM, Frydenberg M, Bangma CH, Remmers S, Roobol MJ; Prostate Cancer Research International: Active Surveillance (PRIAS) consortium. de Vos II, et al. BJU Int. 2025 Aug;136(2):245-253. doi: 10.1111/bju.16727. Epub 2025 Apr 14. BJU Int. 2025. PMID: 40223578 Free PMC article.
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11.
Reza M, Wirth M, Tammela T, Cicalese V, Veiga FG, Mulders P, Miller K, Tubaro A, Debruyne F, Patel A, Caris C, Witjes W, Thorsson O, Wollmer P, Edenbrandt L, Ohlsson M, Trägårdh E, Bjartell A. Reza M, et al. Among authors: veiga fg. Eur Urol Oncol. 2021 Feb;4(1):49-55. doi: 10.1016/j.euo.2019.05.002. Epub 2019 Jun 8. Eur Urol Oncol. 2021. PMID: 31186177 Clinical Trial.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.
Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A; Triptocare Study Group. Martínez-Piñeiro L, et al. BJU Int. 2014 Oct;114(4):608-16. doi: 10.1111/bju.12542. Epub 2014 Apr 4. BJU Int. 2014. PMID: 24806330 Clinical Trial.